Fabry Disease Market Size, Symptoms, Treatment, Causes, Analysis and Pipeline Review, H1 2016

Hexa Reports
Market Research Reports and Insightful Company Profiles
Fabry Disease Market Size, Symptoms, Treatment, Causes,
Analysis and Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Fabry Disease - Pipeline Review, H1 2016', provides an overview of the Fabry
Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fabry
Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved in therapeutic
development for Fabry Disease and features dormant and discontinued projects.
Browse Detail Report With TOC @ http://www.hexareports.com/report/fabry-disease-pipeline-reviewh1-2016/details
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic
review following a stringent set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Hexa Reports
Market Research Reports and Insightful Company Profiles
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fabry Disease
- The report reviews pipeline therapeutics for Fabry Disease by companies and universities/research
institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Fabry Disease therapeutics and enlists all their major and
minor projects
- The report assesses Fabry Disease therapeutics based on drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fabry Disease
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fabry
Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and
focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
Hexa Reports
Market Research Reports and Insightful Company Profiles
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Request A Sample copy of This Report @ http://www.hexareports.com/sample/113829
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fabry Disease Overview 8
Therapeutics Development 9
Pipeline Products for Fabry Disease - Overview 9
Fabry Disease - Therapeutics under Development by Companies 10
Fabry Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Fabry Disease - Products under Development by Companies 14
Fabry Disease - Companies Involved in Therapeutics Development 15
Actelion Ltd 15
Alexion Pharmaceuticals, Inc. 16
Amicus Therapeutics, Inc. 17
Genzyme Corporation 18
greenovation Biotech GmbH 19
iBio, Inc. 20
Browse Full
2016/details
Report
@
http://www.hexareports.com/report/fabry-disease-pipeline-review-h1-
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Hexa Reports
Market Research Reports and Insightful Company Profiles
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Visit Our Blogs: http://hexareports.blogspot.in